BioLife Solutions (BLFS), Brooks Automation Ciollaborate
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
BioLife Solutions, Inc. (Nasdaq: BLFS) and Brooks Automation recently collaborated on a shipping and storage study to support best distribution practices for time and temperature sensitive biologic materials. Both companies serve the high growth regenerative medicine industry and are focused on delivering solutions that enable commercialization of cell-based products, including CAR T-Cells and other cell types, targeting cancer, heart disease, diabetes, stroke, movement disorders and loss.
BioLife's CryoStor and HypoThermosol® cell storage and shipping media are embedded in over 220 customer validations and clinical trials of cellular therapies. Brooks Life Sciences is the leading supplier of devices, tools, services and software for long term biologic sample storage and management.
The study was presented as a poster at the International Society for Cellular Therapy (ISCT) 2016 Annual Meeting in Singapore and can be found here; http://www.biostorage.com/wp-content/uploads/2016/05/ISCT-2016-Brooks-BioLife-Poster-5-19-16-Printed-Version.pdf.
An expanded white paper can be found here: http://www.biolifesolutions.com/wp-content/uploads/2016/10/Biolife_Brooks_Whitepaper_OCT20_REL.pdf
In the study, current practices for cell freezing using a serum-containing home-brew freeze media and shipping using a common foam dry ice container were compared to best practices of using serum-free, clinical grade CryoStor freeze media and the award winning evo Smart Shipper. Cells were frozen, shipped from BioLife to Brooks, transferred to liquid nitrogen storage for 45 days, then shipped back from Brooks to BioLife and assessed for viability and functional recovery. Significant improvement in total cell survival (viability) and faster regrowth (recovery) post-thaw were observed in the cells frozen in CryoStor and shipped in the evo Smart Shipper.
Specific findings included:
- Jurkat T-cells frozen in traditional 95/5% cryomedia and shipped in an EPS container experienced a significant decline in viability immediately post thaw and a delayed return to function 48 hr post-thaw.
- The combination of CryoStor CS5 and the CRYO evo smart shipper afforded superior protection from cryopreservation and transportation stress with no measurable decline in structural and functional viability as a result of freezing, thawing and two cross-country transit events.
- The CRYO evo smart shipper and biologistex™ cloud-based shipment application allow real-time status, tracking and event alarms throughout the entire shipping process, permitting enhanced tracking and knowledge of any environmental excursions as they happen.
- The design of the CRYO evo smart shipper prevented payload warming from dry ice sublimation and maintained the Jurkat T-cells within the desired temperature range throughout transit.
- The BioStore III Cryo storage system safely stored the Jurkat T-cells below -190°C, prevented unauthorized access and monitored all activities to ensure no samples ever crossed Tg (-135°C). With LIMS connectivity, reports and alarms, storage conditions and inventory was available at all times.
Aby J. Mathew, PhD, Chief Technology Officer at BioLife Solutions, commented on the results by stating, "This was a very effective collaboration with Brooks, and provides more evidence to the clinical and research community about the benefits of Brooks' portfolio of sample storage and management tools and for CryoStor, which is optimized to support cells subjected to the stresses of freezing and thawing."
Kevin O'Donnell, Vice President of Cold Chain Standards, Practices, and Compliance at BioLife remarked, "The evo Smart Shipper is designed to protect precious biologic payloads during shipments, by maintaining consistent temperature of the entire payload throughout transit, and while being subjected to challenging ambient temperature environments. This is critical for high value and potentially life-saving cellular therapeutics."
John Fink, Director, Product Marketing for Cryogenic Automation at Brooks, added, "This study further reinforces the need for enhanced and vigilant temperature monitoring of samples during transit and storage. BioStore™ III Cryo and TempAura™ seamlessly provide this capability and are complementary to the evo onboard payload monitoring system and biologistex cold chain logistics SaaS."
BioLife Solutions estimates the addressable market for small format shipping containers and data monitoring systems at $500 million. Brooks estimates the addressable market for sample management at $1.3 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sonoco (SON) Affirms FY16 Outlook; Guides FY17 EPS Below Views
- Sears Holdings (SHLD) Director Mnuchin Resigns Amid Trump Nod
- Amgen (AMGN), Allergan (AGN) Announce Submission of ABP 215 MAA to EMA
Create E-mail Alert Related CategoriesCorporate News
Related EntitiesTwitter, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!